Neovasc Tiara™

[vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” oblique_section=”no” text_align=”left” triangle_shape=”no” css_animation=”” box_shadow_on_row=”no”][vc_column width=”1/3″][vc_single_image image=”4277″ img_size=”full” edgt_css_animation=”” css=”.vc_custom_1559188706426{padding-right: 5% !important;}”][/vc_column][vc_column width=”2/3″ css=”.vc_custom_1430502185201{margin-bottom: 15px !important;padding-left: 0px !important;}”][vc_column_text]

Tiara™ is a novel transcatheter device designed to treat mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death.

[/vc_column_text][vc_column_text]Neovasc is developing the Tiara for the treatment of severe MR, a condition that affects approximately four million patients in the U.S. alone. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated.

The Tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart.

Tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve, rather than being adapted from an aortic valve. Tiara implantation is achieved through a transapical approach and does not require any hemodynamic support.[/vc_column_text][vc_column_text el_class=”bullets”]

Challenges to treatment of the mitral valve include:

  • Complex geometry of the mitral apparatus
  • Changes of the mitral apparatus throughout the cardiac cycle
  • Maintaining continuity with the sub valvular structures
  • Native D shape of the mitral valve
  • Proximity to the aortic valve and potential for Left Ventricular Outflow Tract (LVOT) obstruction
  • Large size of the mitral valve – larger crossing profile
  • High closing pressures
  • Left ventricular remodelling

[/vc_column_text][vc_empty_space image_repeat=”no-repeat”][vc_separator type=”normal” color=”#ed1a3b” border_style=”solid” thickness=”2″ down=”10″][vc_column_text el_class=”sidebar-products”]We invite you to register for Neovasc news alerts to be apprised of Tiara updates as we move through the development program.[/vc_column_text][vc_empty_space height=”45px” image_repeat=”no-repeat”][vc_column_text]


Nkomo, V.T., et al., Lancet, 2006;368(9540):1005-1011
Mirabel, M., et al., Eur Heart J, 2007;28(11):1358-1365
Lamas GA: Circulation 1997;96:827-33
Grigioni F: Circulation 2001;103:1759-64
Ellis SGAm J Cardiol 2002;89:315-8
Sachin S. Goel: JACC 2014 Vol. 63, No. 2

[/vc_column_text][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” oblique_section=”no” text_align=”left” triangle_shape=”no” css_animation=”” box_shadow_on_row=”no” css=”.vc_custom_1430236198757{margin-top: 20px !important;margin-right: 0px !important;margin-bottom: 0px !important;margin-left: 0px !important;padding-top: 35px !important;padding-bottom: 15px !important;background-color: #e0e0e0 !important;}”][vc_column el_class=”footer-facts”][vc_empty_space height=”85px” image_repeat=”no-repeat”][/vc_column][/vc_row]